FIELD: medicine.
SUBSTANCE: invention relates to medicine, and deals with treatment of pathologic states connected with increased level of growth hormone (GH) or insulin-like growth factor 1(IGF). For this purpose realised is complex treatment which includes introduction of growth hormone antagonist and somatostatin or somatostatin analogue in developed doses and regimens.
EFFECT: method ensures normalisation of GH and IGF-1 levels in patients resistant to monotherapy with somatostatin analogues during at least 6-month treatment course.
15 cl, 1 tbl, 1 dwg, 1 ex
